Blood doping and its detection

Blood

Volumn 118, Issue 9, 2011, Pages 2395-2404

  Jelkmann, Wolfgang ^a   Lundby, Carsten ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CNTO 528; CNTO 530; COBALT; ERYTHROPOIETIN; GROWTH HORMONE; HEMOGLOBIN; HYBRID PROTEIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGISENATIDE; PROSTANOID; RECOMBINANT ERYTHROPOIETIN; TESTOSTERONE; THYROID HORMONE; UNCLASSIFIED DRUG;

ATHLETE; BLOOD AUTOTRANSFUSION; BLOOD DOPING; DOPING; DRUG DETERMINATION; EPO GENE; ERYTHROCYTE TRANSFUSION; GENE; GENE TRANSFER; HEMOGLOBIN BLOOD LEVEL; HUMAN; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVIEW;

EID: 80052423299     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-303271     Document Type: Review

References (125)

1. World Anti-Doping Agency. http://www.wada-ama.org/en. Accessed February 2011.
2. World Anti-Doping Agency. Athlete Biological Passport Operating Guidelines. http://www.wada-ama.org/en/Science-Medicine/Athlete-Biological- Passport/Operating-Guidelines. Accessed February 2011.
3. Mercer K.W., Densmore J.J. Hematologic disorders in the athlete. Clin Sports Med. 2005;24(3):599-621. (Pubitemid 40943418)
4. Calbet J.A., Lundby C., Koskolou M., Boushel R. Importance of hemoglobin concentration to exercise: Acute manipulations. Respir Physiol Neurobiol. 2006;151(2):132-140. (Pubitemid 43786162)
5. 2max with no history of training is primarily due to high blood volume. Med Sci Sports Exerc. 2002;34(6):966-971.
6. Pace N., Consolazio W.V., Lozner E.L. The effect of transfusions of red blood cells on the hypoxia tolerance of normal men. Science. 1945;102(2658):589-591.
7. 2max. Exerc Sport Sci Rev. 2010;38(2):68-75.
8. Warburton D.E., Gledhill N., Quinney H.A. Blood volume, aerobic power, and endurance performance: Potential ergogenic effect of volume loading. Clin J Sport Med. 2000;10(1):59-66.
9. Sawka M.N., Convertino V.A., Eichner E.R., Schnieder S.M., Young A.J. Blood volume: Importance and adaptations to exercise training, environmental stresses, and trauma/sickness. Med Sci Sports Exerc. 2000;32(2):332-348. (Pubitemid 30108111)
10. Ekblom B., Berglund B. Effect of erythropoietin administration on maximal aerobic power in man. Scand J Med Sci Sports. 1991;1(2):88-93.
11. Berglund B., Ekblom B. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med. 1991;229(2):125-130.
12. Audran M., Gareau R., Matecki S., et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exerc. 1999;31(5):639-645. (Pubitemid 29205422)
13. Birkeland K.I., Stray-Gundersen J., Hemmersbach P., Hallen J., Haug E., Bahr R. Effect of rhEPO administration on serum levels of sTfR and cycling performance. Med Sci Sports Exerc. 2000;32(7):1238-1243. (Pubitemid 30482652)
14. Thomsen J.J., Rentsch R.L., Robach P., et al. Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity. Eur J Appl Physiol. 2007;101(4):481-486. (Pubitemid 47500366)
15. Lundby C., Olsen N.V. Effects of recombinant human erythropoietin in normal humans. J Physiol. 2011;589(6):1265-1271.
16. Lundby C., Robach P., Boushel R., et al. Does recombinant human Epo increase exercise capacity by means other than augmenting oxygen transport? J Appl Physiol. 2008;105(2):581-587.
17. Lundby C., Hellsten Y., Jensen M.B., Munch A.S., Pilegaard H. Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle. J Appl Physiol. 2008;104(4):1154-1160. (Pubitemid 351507957)
18. Rasmussen P., Foged E.M., Krogh-Madsen R., et al. Effects of erythropoietin administration on cerebral metabolism and exercise capacity in men. J Appl Physiol. 2010;109(2):476-483.
19. Major A., Mathez-Loic F., Rohling R., Gautschi K., Brugnara C. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol. 1997;98(2):292-294. (Pubitemid 27345099)
20. Zotter H., Robinson N., Zorzoli M., Schattenberg L., Saugy M., Mangin P. Abnormally high serum ferritin levels among professional road cyclists. Br J Sports Med. 2004;38(6):704-708. (Pubitemid 39611550)
21. Cazzola M. A global strategy for prevention and detection of blood doping with erythropoietin and related drugs. Haematologica. 2000;85(6):561-563. (Pubitemid 30450933)
22. Nelson M., Popp H., Sharpe K., Ashenden M. Proof of homologous blood transfusion through quantification of blood group antigens. Haematologica. 2003;88(11):1284-1295. (Pubitemid 37456384)
23. Giraud S., Robinson N., Mangin P., Saugy M. Scientific and forensic standards for homologous blood transfusion anti-doping analyses. Forensic Sci Int. 2008;179(1):23-33.
24. Gore C.J., Bourdon P.C., Woolford S.M., Ostler L.M., Eastwood A., Scroop G.C. Time and sample site dependency of the optimized co-rebreathing method. Med Sci Sports Exerc. 2006;38(6):1187-1193. (Pubitemid 43902503)
25. Prommer N., Sottas P.E., Schoch C., Schumacher Y.O., Schmidt W. Total hemoglobin mass: A new parameter to detect blood doping? Med Sci Sports Exerc. 2008;40(12):2112-2118.
26. Banfi G., Lombardi G., Colombini A., Lippi G. A world apart: Inaccuracies of laboratory methodologies in antidoping testing. Clin Chim Acta. 2010;411(15):1003-1008.
27. Lundby C., Robach P. Assessment of total haemoglobin mass: Can it detect erythropoietin-induced blood manipulations? Eur J Appl Physiol. 2010;108(1):197-200.
28. Jelkmann W. Biosimilar epoetins and other "follow-on" biologics: Update on the European experiences. Am J Hematol. 2010;85(10):771-780.
29. Macdougall I.C., Ashenden M. Current and upcoming erythropoiesis- stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis. 2009;16(2):117-130.
30. Lasne F., Martin L., Crepin N., De Ceaurriz J. Detection of isoelectric profiles of erythropoietin in urine: Differentiation of natural and administered recombinant hormones. Anal Biochem. 2002;311(2):119-126. (Pubitemid 35463470)
31. Catlin D.H., Breidbach A., Elliott S., Glaspy J. Comparison of the isoelectric focusing patterns of darbepoetin-alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem. 2002;48(11):2057-2059. (Pubitemid 35222769)
32. Pascual J.A., Belalcazar V., De Bolos C., Gutierrez R., Llop E., Segura J. Recombinant erythropoietin and analogues: A challenge for doping control. Ther Drug Monit. 2004;26(2):175-179. (Pubitemid 38501214)
33. Kohler M., Ayotte C., Desharnais P., et al. Discrimination of recombinant and endogenous urinary erythropoietin by calculating relative mobility values from SDS gels. Int J Sports Med. 2008;29(1):1-6. (Pubitemid 351183231)
34. WADA. Harmonization of the method for the identification of Epoetin alfa and beta (EPO) and Darbepoetin-alfa (NESP) by IEF-double blotting and chemiluminescent detection. http://www.wada-ama.org/rtecontent/document/ td2009eop-en.pdf. Accessed February 2011.
35. Lundby C., Achman-Andersen N.J., Thomsen J.J., Norgaard A.M., Robach P. Testing for recombinant human erythropoietin in urine: Problems associated with current anti doping testing. J Appl Physiol. 2008;105(2):417-419.
36. Lamon S., Robinson N., Sottas P.E., et al. Possible origins of undetectable EPO in urine samples. Clin Chim Acta. 2007;385(1):61-66. (Pubitemid 47374667)
37. Thevis M., Maurer J., Kohler M., Geyer H., Schänzer W. Proteases in doping control analysis. Int J Sports Med. 2007;28(7):545-549. (Pubitemid 47080133)
38. Thomas A., Kohler M., Walpurgis K., Schänzer W., Thevis M. Proteolysis and autolysis of proteases and the detection of degradation products in doping control. Drug Test Anal. 2009;1(2):81-86.
39. Lundby C., Thomsen J.J., Boushel R., et al. Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol. 2007;578(1):309-314. (Pubitemid 44971127)
40. Ashenden M., Varlet-Marie E., Lasne F., Audran M. The effects of microdose recombinant human erythropoietin regimens in athletes. Haematologica. 2006;91(8):1143-1144. (Pubitemid 44204788)
41. Breidbach A., Catlin D.H., Green G.A., Tregub I., Truong H., Gorzek J. Detection of recombinant human erythropoietin in urine by isoelectric focusing. Clin Chem. 2003;49(6):901-907. (Pubitemid 36623469)
42. Elliott S., Lorenzini T., Asher S., et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol. 2003;21(4):414-421. (Pubitemid 36397662)
43. Lamon S., Robinson N., Mangin P., Saugy M. Detection window of Darbepoetin-alpha following one single subcutaneous injection. Clin Chim Acta. 2007;379(1):145-149. (Pubitemid 46366986)
44. Morkeberg J., Lundby C., Nissen-Lie G., Nielsen T.K., Hemmersbach P., Damsgaard R. Detection of darbepoetin-alfa misuse in urine and blood: A preliminary investigation. Med Sci Sports Exerc. 2007;39(10):1742-1747. (Pubitemid 47511481)
45. Macdougall I.C. CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4(6):436-440.
46. Reichel C., Gmeiner G. Erythropoietin and analogs. Handb Exp Pharmacol. 2010;195:251-294.
47. Lasne F., Martin L., Martin J., De Ceaurriz J. Isoelectric profiles of human erythropoietin are different in serum and urine. Int J Biol Macromol. 2007;41(3):354-357. (Pubitemid 46990535)
48. Dumont J.A., Bitonti A.J., Clark D., Evans S., Pickford M., Newman S.P. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med. 2005;18(3):294-303. (Pubitemid 41395731)
49. Fan Q., Leuther K.K., Holmes C.P., et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol. 2006;34(10):1303-1311. (Pubitemid 44389891)
50. Stead R.B., Lambert J., Wessels D., et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, doseescalation study in healthy volunteers. Blood. 2006;108(6):1830-1834. (Pubitemid 44394989)
51. Macdougall I.C., Rossert J., Casadevall N., et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361(19):1848-1855.
52. Bouman-Thio E., Franson K., Miller B., et al. A Phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J Clin Pharmacol. 2008;48(10):1197-1207.
53. Sathyanarayana P., Houde E., Marshall D., et al. CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools. Blood. 2009;113(20):4955-4962.
54. Haase V.H. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol. 2010;299(1):F1-F13.
55. Bruegge K., Jelkmann W., Metzen E. Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr Med Chem. 2007;14(17):1853-1862. (Pubitemid 47163403)
56. Goldwasser E., Jacobson L.O., Fried W., Plzak L.F. Studies on erythropoiesis: V. The effect of cobalt on the production of erythropoietin. Blood. 1958;13(1):55-60.
57. Yuan Y., Hilliard G., Ferguson T., Millhorn D.E. Cobalt inhibits the interaction between hypoxiainducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factoralpha. J Biol Chem. 2003;278(18):15911-15916. (Pubitemid 36799707)
58. Jelkmann W. Efficacy of recombinant erythropoietins: Is there unity of international units? Nephrol Dial Transplant. 2009;24(5):1366-1368.
59. Gardner F.H. The use of cobaltous chloride in the anemia associated with chronic renal disease. J Lab Clin Med. 1953;41(1):56-64.
60. Taylor A., Marks V. Cobalt: A review. J Hum Nutr. 1978;32(3):165-177.
61. Curtis J.R., Goode G.C., Herrington J., Urdaneta L.E. Possible cobalt toxicity in maintenance hemodialysis patients after treatment with cobaltous chloride: A study of blood and tissue cobalt concentrations in normal subjects and patients with terminal and renal failure. Clin Nephrol. 1976;5(2):61-65.
62. Lippi G., Franchini M., Guidi G.C. Blood doping by cobalt: Should we measure cobalt in athletes? J Occup Med Toxicol. 2006;1:18.
63. Safran M., Kim W.Y., O'Connell F., et al. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A. 2006;103(1):105-110. (Pubitemid 43076112)
64. Hsieh M.M., Linde N.S., Wynter A., et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood. 2007;110(6):2140-2147. (Pubitemid 47443933)
65. Fraisl P., Aragones J., Carmeliet P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov. 2009;8(2):139-152.
66. Nagel S., Talbot N.P., Mecinovic J., Smith T.G., Buchan A.M., Schofield C.J. Therapeutic manipulation of the HIF hydroxylases. Antioxid Redox Signal. 2010;12(4):481-501.
67. Bernhardt W.M., Wiesener M.S., Scigalla P., et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010;21(12):2151-2156.
68. Imagawa S., Nakano Y., Obara N., et al. A GATAspecific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB J. 2003;17(12):1742-1744.
69. Nakano Y., Imagawa S., Matsumoto K., et al. Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood. 2004;104(13):4300-4307. (Pubitemid 39620186)
70. Imagawa S., Matsumoto K., Horie M., et al. Does K-11706 enhance performance and why? Int J Sports Med. 2007;28(11):928-933. (Pubitemid 350144585)
71. Binley K., Askham Z., Iqball S., et al. Long-term reversal of chronic anemia using a hypoxiaregulated erythropoietin gene therapy. Blood. 2002;100(7):2406-2413.
72. Lasne F., Martin L., De Ceaurriz J., Larcher T., Moullier P., Chenuaud P. "Genetic doping" with erythropoietin cDNA in primate muscle is detectable. Mol Ther. 2004;10(3):409-410. (Pubitemid 39186104)
73. Gao G., Lebherz C., Weiner D.J., et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood. 2004;103(9):3300-3302. (Pubitemid 38525655)
74. Chenuaud P., Larcher T., Rabinowitz J.E., et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood. 2004;103(9):3303-3304. (Pubitemid 38525656)
75. Rivera V.M., Gao G.P., Grant R.L., et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood. 2005;105(4):1424-1430. (Pubitemid 40223657)
76. Beiter T., Zimmermann M., Fragasso A., et al. Establishing a novel single-copy primer-internal intron-spanning PCR (spiPCR) procedure for the direct detection of gene doping. Exerc Immunol Rev. 2008;14:73-85.
77. Beiter T., Zimmermann M., Fragasso A., et al. Direct and long-term detection of gene doping in conventional blood samples. Gene Ther. 2011;18(3):225-231.
78. Baoutina A., Coldham T., Bains G.S., Emslie K.R. Gene doping detection: Evaluation of approach for direct detection of gene transfer using erythropoietin as a model system. Gene Ther. 2010;17(8):1022-1032.
79. Lippin Y., Dranitzki-Elhalel M., Brill-Almon E., et al. Human erythropoietin gene therapy for patients with chronic renal failure. Blood. 2005;106(7):2280-2286. (Pubitemid 41510797)
80. Sohmiya M., Ishikawa K., Kato Y. Stimulation of erythropoietin secretion by continuous subcutaneous infusion of recombinant human GH in anemic patients with chronic renal failure. Eur J Endocrinol. 1998;138(3):302-306. (Pubitemid 28154780)
81. Kurtz A., Jelkmann W., Bauer C. A new candidate for the regulation of erythropoiesis: Insulin-like growth factor I. FEBS Lett. 1982;149(1):105-108. (Pubitemid 13177107)
82. Urena P., Bonnardeaux A., Eckardt K.U., Kurtz A., Drueke T.B. Insulin-like growth factor I: A modulator of erythropoiesis in uraemic patients? Nephrol Dial Transplant. 1992;7(1):40-44.
83. Shahani S., Braga-Basaria M., Maggio M., Basaria S. Androgens and erythropoiesis: Past and present. J Endocrinol Invest. 2009;32(8):704-716.
84. Johansson P.I., Ullum H., Jensen K., Secher N.H. A retrospective cohort study of blood hemoglobin levels in blood donors and competitive rowers. Scand J Med Sci Sports. 2009;19(1):92-95.
85. Beutler E., Waalen J. The definition of anemia: What is the lower limit of normal of the blood hemoglobin concentration? Blood. 2006;107(5):1747-1750. (Pubitemid 43289347)
86. Gore C.J., Parisotto R., Ashenden M.J., et al. Second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica. 2003;88(3):333-344. (Pubitemid 36358722)
87. Malcovati L., Pascutto C., Cazzola M. Hematologic passport for athletes competing in endurance sports: A feasibility study. Haematologica. 2003;88(5):570-581. (Pubitemid 36648447)
88. Robinson N., Sottas P.E., Mangin P., Saugy M. Bayesian detection of abnormal hematological values to introduce a no-start rule for heterogeneous populations of athletes. Haematologica. 2007;92(8):1143-1144. (Pubitemid 350144226)
89. Parisotto R., Gore C.J., Hahn A.G., et al. Reticulocyte parameters as potential discriminators of recombinant human erythropoietin abuse in elite athletes. Int J Sports Med. 2000;21(7):471-479.
90. Parisotto R., Gore C.J., Emslie K.R., et al. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica. 2000;85(6):564-572. (Pubitemid 30450934)
91. Parisotto R., Wu M., Ashenden M.J., et al. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica. 2001;86(2):128-137. (Pubitemid 32216084)
92. Sharpe K., Hopkins W., Emslie K.R., et al. Development of reference ranges in elite athletes for markers of altered erythropoiesis. Haematologica. 2002;87(12):1248-1257. (Pubitemid 36005299)
93. Sharpe K., Ashenden M.J., Schumacher Y.O. A third generation approach to detect erythropoietin abuse in athletes. Haematologica. 2006;91(3):356-363.
94. Sottas P.E., Robinson N., Saugy M., Niggli O. A forensic approach to the interpretation of blood doping markers. Law Probability Risk. 2008;7(3):191-210.
95. Sottas PE. Statistical classification of abnormal blood profiles in athletes. Int J Biostatistics. 2006;2(1):Article 3.
96. Segura J., Zorzoli M. Distinction between endogenous and exogenous erythropoietin: Marker methods. In: Ghigo E, ed. Hormone Use and Abuse by Athletes. New York, NY: Springer; 2011:151-161.
97. Goodnough L.T., Skikne B., Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood. 2000;96(3):823-833. (Pubitemid 30616842)
98. Damsgaard R., Munch T., Mørkeberg J., Mortensen S.P., Gonzalez-Alonso J. Effects of blood withdrawal and reinfusion on biomarkers of erythropoiesis in humans: Implications for anti-doping strategies. Haematologica. 2006;91(7):1006-1008. (Pubitemid 44023168)
99. Pottgiesser T., Specker W., Umhau M., Dickhuth H.H., Roecker K., Schumacher Y.O. Recovery of hemoglobin mass after blood donation. Transfusion. 2008;48(7):1390-1397.
100. Pottgiesser T., Specker W., Umhau M., Roecker K., Schumacher Y.O. Post-transfusion stability of haemoglobin mass. Vox Sang. 2009;96(2):119-127.
101. Pottgiesser T., Sottas P.E., Echteler T., Robinson N., Umhau M., Schumacher Y.O. Detection of autologous blood doping with adaptively evaluated biomarkers of doping: A longitudinal blinded study [published online ahead of print March 7, 2011]. Transfusion. doi: 10.1111/j.1537-2995.2011.03076.x.
102. Mørkeberg J., Sharpe K., Belhage B., et al. Detecting autologous blood transfusions: A comparison of three passport approaches and four blood markers. Scand J Med Sci Sports. 2011;21(2):235-243.
103. Mørkeberg J., Belhage B., Ashenden M., et al. Screening for autologous blood transfusions. Int J Sports Med. 2009;30(4):285-292.
104. Banfi G., Mauri C., Morelli B., Di Gaetano N., Malgeri U., Melegati G. Reticulocyte count, mean reticulocyte volume, immature reticulocyte fraction, and mean sphered cell volume in elite athletes: Reference values and comparison with the general population. Clin Chem Lab Med. 2006;44(5):616-622. (Pubitemid 43735636)
105. Parisotto R., Ashenden M.J., Gore C.J., Sharpe K., Hopkins W., Hahn A.G. The effect of common hematologic abnormalities on the ability of blood models to detect erythropoietin abuse by athletes. Haematologica. 2003;88(8):931-940. (Pubitemid 37128094)
106. Brugnara C., Colella G.M., Cremins J., et al. Effects of subcutaneous recombinant human erythropoietin in normal subjects: Development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med. 1994;123(5):660-667.
107. Breymann C., Rohling R., Krafft A., Huch A., Huch R. 'Blood doping' with recombinant erythropoietin (rhEPO) and assessment of functional iron deficiency in healthy volunteers. Br J Haematol. 2000;108(4):883-884. (Pubitemid 30304528)
108. Ashenden M.J., Fricker P.A., Ryan R.K., Morrison N.K., Dobson G.P., Hahn A.G. The haematological response to an iron injection amongst female athletes. Int J Sports Med. 1998;19(7):474-478. (Pubitemid 28508610)
109. Diaz V., Lombardi G., Ricci C., Jacobs R.A., Lundby C., Banfi G. Reticulocyte and haemoglobin profiles in elite triathletes over four consecutive seasons. Int J Lab Hematol. In press.
110. Banfi G., Del Fabbro M. Behaviour of reticulocyte counts and immature reticulocyte fraction during a competitive season in elite athletes of four different sports. Int J Lab Hematol. 2007;29(2):127-131. (Pubitemid 46911164)
111. Major A., Bauer C., Breymann C., Huch A., Huch R. rh-erythropoietin stimulates immature reticulocyte release in man. Br J Haematol. 1994;87(3):605-608. (Pubitemid 24230030)
112. Krzyzanski W., Perez-Ruixo J.J. An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects. Pharm Res. 2007;24(4):758-772. (Pubitemid 46411964)
113. Russell G., Gore C.J., Ashenden M.J., Parisotto R., Hahn A.G. Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise. Eur J Appl Physiol. 2002;86(5):442-449. (Pubitemid 41399062)
114. Souillard A., Audran M., Bressolle F., Gareau R., Duvallet A., Chanal J.L. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control. Br J Clin Pharmacol. 1996;42(3):355-364. (Pubitemid 26284425)
115. Casoni I., Ricci G., Ballarin E., et al. Hematological indices of erythropoietin administration in athletes. Int J Sports Med. 1993;14(6):307-311. (Pubitemid 23259998)
116. Breymann C., Bauer C., Major A., et al. Optimal timing of repeated rh-erythropoietin administration improves its effectiveness in stimulating erythropoiesis in healthy volunteers. Br J Haematol. 1996;92(2):295-301. (Pubitemid 26042922)
117. Ashenden M.J., Gore C.J., Parisotto R., Sharpe K., Hopkins W.G., Hahn A.G. Effect of altitude on second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica. 2003;88(9):1053-1062. (Pubitemid 37151157)
118. Abellan R., Ventura R., Remacha A.F., Rodriguez F.A., Pascual J.A., Segura J. Intermittent hypoxia exposure in a hypobaric chamber and erythropoietin abuse interpretation. J Sports Sci. 2007;25(11):1241-1250. (Pubitemid 47180518)
119. McLaren HR. CAS doping jurisprudence: what can we learn? Int Sports Law Rev. 2006;Issue 1:4-22.
120. Bornø A., Aachmann-Andersen N.J., Munch-Andersen T., Hulston C.J., Lundby C. Screening for recombinant human erythropoietin using [Hb], reticulocytes, the OFF(hr score), OFF (z score) and Hb (z score): Status of the Blood Passport. Eur J Appl Physiol. 2010;109(3):537-543.
121. Faber K., Sjerps M. Anti-doping researchers should conform to certain statistical standards from forensic science. Sci Justice. 2009;49(3):214-215.
122. Sottas P.E., Saudan C., Saugy M. Doping: A paradigm shift has taken place in testing. Nature. 2008;455(720):166.
123. Kayser B., Mauron A., Miah A. Current anti-doping policy: A critical appraisal. BMC Med Ethics. 2007;8:2.
124. Meinhardt U., Nelson A.E., Hansen J.L., et al. The effects of growth hormone on body composition and physical performance in recreational athletes: A randomized trial. Ann Intern Med. 2010;152(9):568-577.
125. Jelkmann W. Erythropoiesis stimulating agents and techniques: A challenge for doping analysts. Curr Med Chem. 2009;16(10):1236-1247.